These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6360031)

  • 1. Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease.
    Jotkowitz S
    Ann Neurol; 1983 Dec; 14(6):690-1. PubMed ID: 6360031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
    Wettstein A
    Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memory enhancement with oral physostigmine in Alzheimer's disease.
    N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral physostigmine and lecithin improve memory in Alzheimer disease.
    Thal LJ; Fuld PA; Masur DM; Sharpless NS
    Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortisol responses to cholinergic drugs in Alzheimer's disease.
    Kumar V; Smith RC; Sherman KA; Ashford W; Murphy J; Giacobini E; Colliver J
    Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):471-6. PubMed ID: 3069749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral physostigmine in Alzheimer's disease.
    Davis KL; Mohs RC; Davis BM; Horvath TB; Greenwald BS; Rosen WG; Levy MI; Johns CA
    Psychopharmacol Bull; 1983; 19(3):451-3. PubMed ID: 6635123
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral physostigmine treatment of patients with Alzheimer's disease.
    Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL
    Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma.
    Peskind ER; Wingerson D; Pascualy M; Thal L; Veith RC; Dorsa DM; Bodenheimer S; Raskind MA
    Biol Psychiatry; 1995 Oct; 38(8):532-8. PubMed ID: 8562665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
    Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
    Asthana S; Greig NH; Hegedus L; Holloway HH; Raffaele KC; Schapiro MB; Soncrant TT
    Clin Pharmacol Ther; 1995 Sep; 58(3):299-309. PubMed ID: 7554703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term administration of oral physostigmine and lecithin improve memory in Alzheimer's disease.
    Levin HS; Peters BH
    Ann Neurol; 1984 Feb; 15(2):210. PubMed ID: 6703661
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outpatient treatment of senile dementia with oral physostigmine.
    Beller SA; Overall JE; Rhoades HM; Swann AC
    J Clin Psychiatry; 1988 Oct; 49(10):400-4. PubMed ID: 3049561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term administration of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.
    Davidson M; Bierer LM; Kaminsky R; Ryan TM; Davis KL
    Alzheimer Dis Assoc Disord; 1989; 3(4):224-7. PubMed ID: 2688700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
    Asthana S; Raffaele KC; Berardi A; Greig NH; Haxby JV; Schapiro MB; Soncrant TT
    Alzheimer Dis Assoc Disord; 1995; 9(4):223-32. PubMed ID: 8749612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.